---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-25-000050"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:38:56.144772+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics Q1 net loss $44.8M; cash $564.8M; on track for Phase 2 starts mid-2025

## Summary
- Cash, cash equivalents, and marketable securities of $564.8M as of March 31, 2025.
- Net loss of $44.8M for Q1 2025 vs. $43.9M in Q1 2024; R&D expenses rose to $41.6M.
- Extended Phase 1 data for SPY001 supports potential quarterly or biannual dosing; Phase 2 initiation planned mid-2025.
- Interim Phase 1 data for SPY002 expected Q2 2025; first participant dosed in Phase 1 trial of SPY003.
- Plan to initiate Phase 2 trials in UC and RA mid-2025 with 7+ proof-of-concept readouts in 2026-2027.

## SEC filing metadata
- accession: 0001636282-25-000050
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/0001636282-25-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/syre-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-25-000050
- JSON: https://secwatch.observer/filing/0001636282-25-000050.json
- Plain text: https://secwatch.observer/filing/0001636282-25-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.